Abstract
LBP16 - MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have